Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.  |
AIDS TREATMENT NEWS "alert" March 18, 2004
John S. James
An important study by cardiologists, endocrinologists, and HIV physicians found more atherosclerosis in persons with HIV, and much faster progression, than in the general population.1 The measurement used in this study -- increasing thickness of the carotid artery, determined non-invasively by ultrasound examination -- is known to be a predictor of strokes and heart attacks in other populations. But this study could not tell how much of the increased risk is due to HIV itself, and how much is due to metabolic abnormalities caused by protease inhibitors or other HAART treatment in some patients.2
Age, LDL cholesterol, and smoking (cigarette pack-years) were strong predictors of atherosclerosis in the 148 persons with HIV who were studied; Latino race and high blood pressure were weaker predictors. Other risks like diabetes would not have shown up in this study because of the small number of volunteers affected. When matched controls were added to the analysis, HIV infection itself was a strong predictor of greater atherosclerosis, independent of other factors.
The authors gave some practical clinical suggestions at the end of the article: "Although randomized trials have not been done to demonstrate that treatment of risk factors reduces events in HIV-infected patients, it seems reasonable to extrapolate from other populations and to recommend aggressive control of risk factors. Smoking is particularly important because of its high prevalence. Hypertension should be treated. LDL cholesterol should be reduced to low levels, and hypertriglyceridemia should be controlled. If lipids are difficult to control, antiretroviral medication that may be contributing to lipid elevation should be reviewed and changed to medication with fewer lipid effects. Until further data are available, treating to the National Cholesterol Education Panel guidelines3 for patients with established vascular disease or diabetes seems prudent."
The researchers are from San Francisco General Hospital, and the Department of Medicine, University of California, San Francisco. The volunteers were mostly recruited from the University of California, San Francisco Study of the Consequences of the Protease Inhibitor Era (SCOPE) study.
References
| 1. | PY Hsue, JC Lo, A Franklin, AF Bolger, JN Martin, SG Deeks, and DD Waters. "Progression of Atherosclerosis as Assessed by Carotid Intima-Media Thickness in Patients With HIV Infection". Circulation. 2004 Apr 6;109(13):1603-8 (published online before print, March 15). The abstract is free at: http://www.circulationaha.org - but the full article costs $15 online for nonsubscribers. |
| 2. | Another recent study looked at triglyceride and cholesterol changes associated with different antiretrovirals, in a major analysis of data from over 7,000 HIV patients in 11 previously established cohorts. Some of its findings will be useful for particular patients, but overall it is hard to interpret this article. Reuters Health published a summary; you can find it on the AIDSMEDS site, at: http://www.aidsmeds.com/news/20040323clin001.html Here is the reference for the original article: |
| 3. | Information on the National Cholesterol Education Program is available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm |
040318
ATN040302
Copyright © 2004 - by John S. James. See "Permission to Copy" at: http://www.aidsnews.org/canhelp. How to help AIDS Treatment News: http://www.aidsnews.org/canhelp.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .